[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • METHODS: Between 1980 and 2000, 686 endometrial carcinoma patients underwent primary surgery at our institution.
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • All underwent surgery and assessment of peritoneal cytology.
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • Patients with clear +/- adenocarcinoma histology had a similar 5-year disease-free survival (38.8% vs. 38.7%, p = 0.95) compared with those with clear-cell + other unfavorable histologies.
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • Of the 26 women with clear-cell +/- adenocarcinoma histology, only 1 (3.8%) relapsed in the abdomen.
  • Unlike papillary serous tumors, clear-cell carcinoma does not seem to have a high propensity for abdominal failure.
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometrial Neoplasms / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


2. Hill KA, Rosen B, Shaw P, Causer PA, Warner E: Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report. Gynecol Oncol; 2007 Oct;107(1):136-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental MRI detection of BRCA1-related solitary peritoneal carcinoma during breast screening--A case report.
  • BACKGROUND: The reported cumulative risk of developing primary peritoneal carcinoma (PPC) one to 20 years after prophylactic bilateral oophorectomy is 3.5% to 4.3%.
  • After four cycles of chemotherapy a localized, grade 3 serous papillary adenocarcinoma was resected followed by further chemotherapy and radiation.
  • She remains disease-free 3 years post-treatment.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Genes, BRCA1. Peritoneal Neoplasms / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17629551.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Takano M, Yoshikawa T, Kato M, Aida S, Goto T, Furuya K, Kikuchi Y: Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature. Eur J Gynaecol Oncol; 2009;30(5):575-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell carcinoma of the peritoneum: report of two cases and a review of the literature.
  • The most common neoplasms of the peritoneum are malignant mesothelioma and serous papillary adenocarcinoma.
  • Adjuvant chemotherapy using irinotecan and cisplatin was effective in one case.
  • The cases and a review of the literature suggested that residual tumor volume size determines the survival of these patients, and that the tumors show resistance to conventional platinum-based chemotherapy.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Antineoplastic Combined Chemotherapy Protocols. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Humans. Middle Aged

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Eur J Gynaecol Oncol. 2010;31(1):4. Yoshokawa, T [corrected to Yoshikawa, T]
  • (PMID = 19899421.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 15
  •  go-up   go-down


Advertisement
4. Bafghi A, Zafrani Y, Pautier P, Lhommé C, Duvillard P, Castaigne D, Haie-Meder C, Morice P: Endometrial disorders in patients with peritoneal serous papillary carcinoma. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):101-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrial disorders in patients with peritoneal serous papillary carcinoma.
  • BACKGROUND: The purpose of this study was to evaluate the incidence rate of endometrial disease, particularly endometrial carcinoma, in patients with primary peritoneal serous papillary carcinoma (PSPC).
  • RESULTS: Six patients underwent primary debulking surgery and 26 underwent interval debulking surgery after 3 or 4 courses of platinum-based chemotherapy.
  • Two patients had endometrioid adenocarcinoma of the uterine body (stage IA grade 1 in one case, and stage IB grade 1 in the other) associated with the PSPC.
  • This result suggests that systematic hysterectomy should be performed at the time of debulking surgery in PSPC, even in the absence of peritoneal spread within pelvic cavity.
  • [MeSH-major] Adenocarcinoma / complications. Cystadenocarcinoma, Serous / complications. Endometrial Hyperplasia / complications. Endometrial Neoplasms / complications. Peritoneal Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16860923.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


5. Miyake Y, Kato T, Oshima S, Iijima S, Kurokawa E, Okamoto Y, Kumazawa K, Chin R, Amemiya K, Adachi K, Kikkawa N: [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2317-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary].
  • Under diagnosis of a primary rectal cancer with peritonitis, an ileostomy was scheduled.
  • Since peritoneal dissemination was found, histologically she was diagnosed as metastatic rectal cancer from serous adenocarcinoma of the ovary.
  • Chemotherapy with paclitaxel and carboplatin was performed, and complete disappearance on assessable examination was seen.
  • No viable cancer tissue could be found.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology. Rectal Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Paclitaxel / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Lin BT, Gown AM: Mixed carcinoid and adenocarcinoma of the appendix: report of 4 cases with immunohistochemical studies and a review of the literature. Appl Immunohistochem Mol Morphol; 2004 Sep;12(3):271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed carcinoid and adenocarcinoma of the appendix: report of 4 cases with immunohistochemical studies and a review of the literature.
  • Four cases of mixed carcinoid and adenocarcinoma of the appendix were reported.
  • Two patients had multiple peritoneal implants mimicking primary peritoneal serous adenocarcinoma or carcinomatosis.
  • Immunohistochemical stains were helpful to separate these tumors from carcinoid tumors and primary peritoneal serous adenocarcinoma.
  • Peritoneal serous adenocarcinomas were CK20 negative.
  • These cases were clinically aggressive, and 1 patient had multiple recurrences and responded partially to chemotherapy.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15551743.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Chromogranin A; 0 / Chromogranins; 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Synaptophysin
  • [Number-of-references] 24
  •  go-up   go-down


7. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR: Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol; 2003 Jan 15;21(2):283-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
  • PURPOSE: To evaluate the feasibility, toxicity, and efficacy of single-agent monoclonal antibody therapy targeting the human epidermal growth factor receptor 2 (HER2)/neu receptor in ovarian and primary peritoneal carcinoma.
  • PATIENTS AND METHODS: Eligible patients had measurable persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with 2+ or 3+ HER2 overexpression documented by immunohistochemistry.
  • Patients without progressive disease or excessive toxicity could continue treatment indefinitely.
  • Those with stable or responding disease at 8 weeks were offered treatment at a higher weekly dose (4 mg/kg) at time of progression.
  • Forty-five patients, all of whom received prior chemotherapy, were entered, and 41 were deemed eligible and assessable.
  • There were only mild expected toxicities and no treatment-related deaths.
  • Serum concentrations of trastuzumab gradually increased with continued therapy.
  • Median treatment duration was 8 weeks (range, 2 to 104 weeks), and median progression-free interval was 2.0 months.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Receptor, ErbB-2 / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal, Humanized. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Middle Aged. Trastuzumab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Trastuzumab .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525520.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab
  •  go-up   go-down


8. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, Groshen S, Swenson S, Markland F, Gandara D, Scudder S, Morgan R, Chen H, Lenz HJ, Oza AM: Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol; 2008 Jan 1;26(1):76-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metronomic chemotherapy, defined as frequent administration of low doses of cytotoxic chemotherapy, suppresses tumor growth, possibly by inhibiting angiogenesis.
  • PATIENTS AND METHODS: Patients with measurable disease and prior treatment with a platinum-containing regimen were eligible.
  • Treatment consisted of bevacizumab 10 mg/kg intravenously every 2 weeks and oral cyclophosphamide 50 mg/d.
  • The primary end point was progression-free survival at 6 months.
  • The probability of being alive and progression free at 6 months was 56% (+/- 6% SE).
  • Median time to progression and survival were 7.2 and 16.9 months, respectively.
  • There were three treatment-related deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Administration, Oral. Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. California. Chicago. Cyclophosphamide / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. E-Selectin / metabolism. Female. Humans. Middle Aged. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology. Prognosis. Survival Rate. Thrombospondin 1 / metabolism. Treatment Outcome. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18165643.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / CM-17102; United States / NCI NIH HHS / CM / CM17107; United States / NCI NIH HHS / CM / CM62203; United States / NCI NIH HHS / CM / N01 CM62209; United States / NCI NIH HHS / CA / P30 CA 14089
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / E-Selectin; 0 / Thrombospondin 1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. Ichimura T, Ishiko O, Nishimura S, Kojima T, Shimura K: Primary peritoneal clear cell carcinoma: excellent results from paclitaxel and carboplatin combination chemotherapy. Oncol Rep; 2001 Nov-Dec;8(6):1243-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal clear cell carcinoma: excellent results from paclitaxel and carboplatin combination chemotherapy.
  • While papillary serous adenocarcinomas are histocytologically common in primary peritoneal carcinomas, clear cell carcinomas are rare.
  • We report a new regimen for the treatment of recurrent clear cell carcinomas of the peritoneum.
  • Paclitaxel and carboplatin combination chemotherapy may be effective in preventing the recurrence of peritoneal carcinomas.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Peritoneal Neoplasms / drug therapy

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11605041.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


10. Agarwal R, Sharma S, Guleria K, Radhakrishnan G, Radhika AG: Primary peritoneal carcinoma: a diagnostic dilemma. Arch Gynecol Obstet; 2010 Jul;282(1):115-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal carcinoma: a diagnostic dilemma.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Age Factors. Biopsy. Colon / pathology. Female. Humans. Middle Aged. Omentum / pathology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Arch Gynecol Obstet. 2010 Mar;281(3):561-4 [19693524.001]
  • (PMID = 20043172.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] Germany
  •  go-up   go-down


11. Nishio S, Kawata T, Harada C, Kawagoe H, Fujiyoshi K, Ishimatsu J, Tsunawaki A, Sugiyama T, Kamura T: [A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel]. Gan To Kagaku Ryoho; 2002 Feb;29(2):309-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of extraovarian primary peritoneal carcinoma successfully treated with weekly paclitaxel].
  • We report the use of paclitaxel in the successful treatment of a 74-year-old patient with extraovarian primary peritoneal carcinoma and acute renal failure caused by intraperitoneal cisplatin.
  • The histological diagnosis was papillary serous adenocarcinoma.
  • She showed a clinical response after three cycles, and then underwent secondary cytoreductive surgery after which she received one additional cycle of therapy.
  • She enjoyed a favorable quality of life without evidence of disease for 16 months after the completion of this therapy.
  • Weekly 1-hour paclitaxel (70 mg/m2) was well tolerated, yet was effective for extraovarian primary peritoneal carcinoma.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Cystadenocarcinoma, Papillary / drug therapy. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Aged. Cisplatin / adverse effects. Drug Administration Schedule. Female. Humans

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11865640.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


12. Suh JH, Kim YH, Chang ED: Primary papillary serous carcinoma of the peritoneum diagnosed by video-assisted thoracoscopic surgery: report of a case. Surg Today; 2008;38(8):743-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary papillary serous carcinoma of the peritoneum diagnosed by video-assisted thoracoscopic surgery: report of a case.
  • Chest radiographs and chest computed tomography (CT) showed right pleural effusion with bilateral pleural masses.
  • A frozen section specimen suggested a papillary adenocarcinoma, which was confirmed to be metastatic primary papillary serous carcinoma of the peritoneum by immunohistochemistry, an elevated serum cancer antigen (CA-125) level, and abdominal CT findings.
  • We found that the patient had been unfortunately misdiagnosed to have advanced colon cancer 11 years previously and thus had undergone a right hemicolectomy which was followed by six cycles of 5-fluorouracil chemotherapy.
  • The patient was transferred to an oncologist to receive the proper chemotherapy with paclitaxel and carboplatin.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / surgery. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / surgery. Thoracic Surgery, Video-Assisted

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2000;35(7):540-7 [10905363.001]
  • [Cites] Clin Radiol. 2001 Sep;56(9):740-5 [11585395.001]
  • [Cites] Adv Clin Path. 2001 Jul;5(3):99-104 [11753882.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(2):197-9 [16620072.001]
  • [Cites] Cancer. 1998 Mar 1;82(5):860-6 [9486574.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):764-70 [14675312.001]
  • [Cites] Oncology. 2005;68(4-6):293-8 [16020955.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):762-8 [17383715.001]
  • [Cites] Gynecol Oncol. 1995 Jun;57(3):433-5 [7774852.001]
  • (PMID = 18668320.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


13. Varras M, Akrivis Ch, Bellou A, Malamou-Mitsi VD, Antoniou N, Tolis C, Salamalekis E: Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up. Eur J Gynaecol Oncol; 2004;25(5):640-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary fallopian tube adenocarcinoma: preoperative diagnosis, treatment and follow-up.
  • We present herein the case of a 58-year-old woman with primary fallopian tube carcinoma that was diagnosed preoperatively on the basis of a positive for adenocarcinoma Papanicolaou vaginal smear, repeated episodes of vaginal bleeding, negative endocervical and endometrial curettage, characteristic features on ultrasonography and elevated CA-125 levels.
  • Pathologic confirmation of primary serous papillary adenocarcinoma of the left fallopian tube was made.
  • Peritoneal washings were positive for malignancy.
  • FIGO stage was considered as IIIb and the patient received six courses of combined carboplatin-taxol chemotherapy.
  • At two years from onset of therapy the patient underwent a modified radical mastectomy and lymphadenectomy because of primary carcinoma of the right breast.
  • The patient was started on tamoxifen therapy, which she is still taking.
  • In conclusion, our study suggests an association between fallopian tube carcinoma and breast cancer and a good response of the patient to platinum-based chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Estrogen Antagonists / therapeutic use. Female. Humans. Mastectomy. Middle Aged. Neoplasm Staging. Postoperative Period. Preoperative Care. Tamoxifen / therapeutic use

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493187.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Antagonists; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


14. Costa MJ, Hansen CL, Holden JA, Guinee D Jr: Topoisomerase II alpha: prognostic predictor and cell cycle marker in surface epithelial neoplasms of the ovary and peritoneum. Int J Gynecol Pathol; 2000 Jul;19(3):248-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We test the hypothesis that the percentage of TopoIIa immunoreactive nuclei (TopoIIaI) aids in the treatment and prognostic evaluation of ovarian and primary peritoneal surface epithelial neoplasms (SENs) and correlates with established cell cycle control markers: p53, p21WAF1/CIP1 (p21), and Ki67.
  • TopoIIaI correlated with SEN architectural/nuclear grade (p < 10(-5)/10(-7)), but not histologic type.
  • The patients in this retrospective series of SEN were treated primarily with platinum-based chemotherapy.
  • These data may suggest further prospective studies in which patients with SENs exhibiting high TopoIIaI are treated with chemotherapy targeted against TopoIIa (e.g., etoposide).
  • In this retrospective series, high SEN TopoIIaI predicted poor survival when treated with platinum-based chemotherapy, which does not target TopoIIa.
  • [MeSH-major] Biomarkers / analysis. Cell Cycle. DNA Topoisomerases, Type II / analysis. Ovarian Neoplasms / enzymology. Peritoneal Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / enzymology. Adenocarcinoma, Mucinous / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Cell Nucleus / enzymology. Cell Nucleus / pathology. Cystadenocarcinoma, Serous / enzymology. Cystadenocarcinoma, Serous / pathology. Endometrium / pathology. Female. Humans. Ki-67 Antigen / analysis. Middle Aged. Neoplasm Metastasis. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10907174.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Ki-67 Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


15. Veroni S, Terzopoulou K, Anagnostopoulou I, Vassilakaki T, Grammatoglou X, Rammou R: Extraovarian peritoneal serous papillary carcinoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):879-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraovarian peritoneal serous papillary carcinoma: a case report.
  • BACKGROUND: Extraovarian peritoneal serous papillary carcinoma (EPSPC) is a rare cancer closely related to ovarian carcinoma and characterized by abdominal carcinomatosis without an identifiable abdominal primary tumor.
  • Peritoneal carcinomatosis without involvement of the ovaries was found.
  • Paracentesis of the ascitic fluid resulted in a positive cytologic report not further suggestive of the malignancy origin, balancing between a mesothelioma and an adenocarcinoma.
  • The histologic and immunohistochemical study of peritoneal biopsy specimens resulted in the diagnosis of EPSPC.
  • CONCLUSION: The combination of cytology, histology, immunohistochemistry and clinical data is a reliable method for the preoperative diagnosis of EPSPC, allowing prompt chemotherapy as surgery may not be indicated in most cases.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovary / pathology. Peritoneal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053561.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


16. Bilgin T, Ozuysal S, Cankiliç H: Primary psammocarcinoma of the peritoneum. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:129-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary psammocarcinoma of the peritoneum.
  • Psammocarcinoma is a rare type of serous carcinoma arising from the ovaries or the peritoneum.
  • Histopathologically, it has large deposits of psammoma bodies, invasion to surrounding tissues, and low-grade cytologic atypia.
  • Biologic behavior is similar to borderline serous tumors with a favorable survival time.
  • Primary surgical debulking with complete resection of the tumor should be the main surgical approach, while the benefit of postoperative chemotherapy remains unknown.
  • A new case of primary peritoneal psammocarcinoma with survival after an initial diagnosis of 5.5 years is presented with a literature review.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Carboplatin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Paclitaxel / administration & dosage. Treatment Outcome

  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515580.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 11
  •  go-up   go-down


17. Matsuo K, Bond VK, Eno ML, Im DD, Rosenshein NB: Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. Int J Cancer; 2009 Dec 1;125(11):2721-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer.
  • The objective of this study was to evaluate the role of an in vitro drug resistance assay to platinum and taxane in the management of advanced epithelial ovarian, fallopian and primary peritoneal cancer.
  • All patients with FIGO Stage IIIc and IV who received postoperative chemotherapy with platinum and taxane for more than 4 courses after the initial cytoreductive surgery between 1995 and 2008 were evaluated.
  • Patients who received neoadjuvant chemotherapy were not included.
  • An in vitro drug resistance assay (EDR Assay, Oncotech, Tustin, CA) was used to determine drug resistance for each patient's tumor tissue.
  • Level of drug resistance was described as extreme (EDR), intermediate (IDR), or low (LDR).
  • Response to chemotherapy and survival were correlated to the EDR Assay.
  • Of the 335 patients who underwent primary cytoreductive surgery, 173 cases met the criteria for statistical evaluation.
  • In conclusion, LDR to both platinum and taxane chemotherapy, as determined by an in vitro drug resistance assay, independently predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer, especially in those patients who undergo optimal primary cytoreduction.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biological Assay / methods. Drug Resistance, Neoplasm. Fallopian Tube Neoplasms / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / mortality. Adenocarcinoma, Clear Cell / secondary. Bridged Compounds / administration & dosage. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / mortality. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / mortality. Endometrial Neoplasms / secondary. Female. Humans. In Vitro Techniques. Lymphatic Metastasis. Middle Aged. Organoplatinum Compounds / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage


18. Kaira K, Takise A, Endou K, Yanagitani N, Sunaga N, Mori M: A case of primary peritoneal serous papillary carcinoma initially presented by massive bilateral pleural effusions. Eur J Gynaecol Oncol; 2006;27(2):197-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary peritoneal serous papillary carcinoma initially presented by massive bilateral pleural effusions.
  • Primary peritoneal serous papillary carcinoma (PSPC) is a rare primary peritoneal tumor.
  • Chest computed tomography (CT) revealed irregular pleural thickening and a small amount of ascites.
  • Adenocarcinoma cells were found via cytologic examination in bilateral pleural fluids and ascites.
  • Because the primary site of the adenocarcinoma was not found, a surgical biopsy of the right pleural thickening was performed.
  • The patient was treated with platinum-based chemotherapy.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / drug therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / drug therapy. Pleural Effusion / diagnosis
  • [MeSH-minor] Aged. CA-125 Antigen / blood. Female. Humans. Tomography, X-Ray Computed

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620072.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


19. Cheng X, Moroney JW, Levenback CF, Fu S, Jaishuen A, Kavanagh JJ: What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies? J Chemother; 2009 Nov;21(5):566-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
  • The aim of this retrospective analysis was to investigate the efficacy and adverse effects of the monoclonal antivascular endothelial growth factor antibody bevacizumab (Avastin(R)) combined with chemotherapeutic agents in non-protocol patients with recurrent ovarian, fallopian tube, or primary peritoneal malignancies.
  • Using our databases, we identified patients treated with bevacizumab combination therapy since June 2005.
  • The median patient age was 58 years, and they had undergone a median of 4.5 (range, 1-10) prior cytotoxic chemotherapy regimens.
  • A median of 4 cycles of therapy with a median bevacizumab dose of 3,600 mg (range, 500-18,240) were administered.
  • Bevacizumab combined with chemotherapy showed promising clinical benefits, with significant response of serum CA125 concentration and moderate adverse effects.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Fallopian Tube Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Antibodies, Monoclonal, Humanized. Bevacizumab. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / secondary. Drug Therapy, Combination. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19933049.001).
  • [ISSN] 1973-9478
  • [Journal-full-title] Journal of chemotherapy (Florence, Italy)
  • [ISO-abbreviation] J Chemother
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Taxoids; 2S9ZZM9Q9V / Bevacizumab; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


20. Elnemr A, Yonemura Y, Shinbo M, Nishino E: Primary retroperitoneal mullerian adenocarcinoma. Rare Tumors; 2010;2(1):e6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary retroperitoneal mullerian adenocarcinoma.
  • Ultrasonography (US) and computed tomography (CT) demonstrated a 15×10 cm cystic mass in the left lower retroperitoneum.
  • The histopathology was reported as mucinous adenocarcinoma of the retroperitoneum.
  • Six cycles of intraperitoneal (IP) chemotherapy was administered during the last six months after diagnosis of recurrence by aspiration cytology and high serum tumor markers (CEA, CA19-9).
  • A few days ago, positron emission tomographic (PET) scanning showed evidence of local recurrence and single vertebral metastasis, so she was admitted again for systemic chemotherapy.
  • Meticulous revision of additional sections of the tumor revealed papillary, serous, mucinous, and endometrioid subtypes of the mullerian adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139951.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994487
  • [Keywords] NOTNLM ; adenocarcinoma / mullerian tumor / retroperitoneum
  •  go-up   go-down


21. Gütgemann I, Lehman NL, Jackson PK, Longacre TA: Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma. Mod Pathol; 2008 Apr;21(4):445-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clear cell carcinoma is a clinically and pathologically distinct entity among surface epithelial ovarian neoplasms, recognized for its resistance to standard platinum-based chemotherapy at advanced stage disease and poor prognosis.
  • We investigated Emi1 protein expression in ovarian neoplasms using a tissue microarray constructed from 339 primary ovarian surface epithelial (serous, endometrioid, clear cell, and mucinous) and peritoneal (serous) neoplasms, stromal and mesenchymal tumors, germ cell tumors, and normal ovarian tissue.
  • In contrast, only 10% (17/177) primary ovarian and primary peritoneal serous carcinomas, 0% (0/10) mucinous carcinomas, and 19% (6/32) endometrioid carcinomas exhibited significant Emi1 protein overexpression.
  • Emi1 protein expression was present in mixed endometrioid/clear cell tumors but absent in tumors with mixed serous/clear cell histology.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Cell Cycle Proteins / biosynthesis. F-Box Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Signal Transduction / physiology. Ubiquitin-Protein Ligase Complexes / metabolism
  • [MeSH-minor] Anaphase-Promoting Complex-Cyclosome. Cyclin E / metabolism. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Receptors, Estrogen / metabolism. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18204430.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / F-Box Proteins; 0 / FBXO5 protein, human; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; EC 6.3.2.19 / Anaphase-Promoting Complex-Cyclosome; EC 6.3.2.19 / Ubiquitin-Protein Ligase Complexes
  •  go-up   go-down


22. Ohwada M, Suzuki M, Suzuki T, Hiratsuka M, Kawai T, Saito K, Sato I: Problems with peritoneal cytology in second-look laparotomy performed in patients with epithelial ovarian carcinoma. Cancer; 2001 Dec 25;93(6):376-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Problems with peritoneal cytology in second-look laparotomy performed in patients with epithelial ovarian carcinoma.
  • In the current study, the accuracy of peritoneal cytology as an evaluation method of SLL was examined.
  • METHODS: The positive SLL rate and the diagnostic accuracy of peritoneal cytology were evaluated in 101 patients with epithelial ovarian carcinoma.
  • The factors considered to be high risk factors for a positive SLL were advanced disease (Stages III and IV by the International Federation of Gynecology and Obstetrics [FIGO] classification), serous adenocarcinoma, and maximum residual tumor > 2 cm after primary surgery (P < 0.05).
  • Of the 23 patients found to be positive on SLL, peritoneal cytology was positive in 6 patients, in whom the percentage was low (26%).
  • Of these 17 patients, the tumor tissues were found to be capsulated completely with connective tissues in all biopsy specimens from 9 patients (53%) and in all but 1 biopsy specimen in 6 patients (35%), together accounting for a capsulation rate of 88%.
  • Conversely, clear exposure of the tumor tissues was observed in at least two biopsy specimens in those patients demonstrating positive cytology (P < 0.01).
  • CONCLUSIONS: Peritoneal cytology in SLL was found to result in a high false-negative rate.
  • One of the reasons for this was considered to be capsulation of the lesions with proliferated connective tissues, which may have been the result of by chemotherapy.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Cancer (Cancer Cytopathol) Copyright 2001 American Cancer Society.
  • (PMID = 11748577.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Kuscu E, Oktem M, Haberal A, Erkanli S, Bilezikci B, Demirhan B: Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review. Eur J Gynaecol Oncol; 2003;24(6):557-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of advanced-stage primary carcinoma of the fallopian tube: case report and literature review.
  • Primary carcinoma of the fallopian tube is a very unusual gynecologic malignancy that accounts for less than 1% of all malignancies of the female genitalia.
  • Frozen-section analysis identified the mass as a serous adenocarcinoma.
  • Total abdominal hysterectomy, bilateral salpingo-oophorectomy, appendectomy, omentectomy, pelvic and para-aortic lymph node dissection, and peritoneal washing were performed.
  • The definitive histopathological diagnosis was primary serous adenocarcinoma of the fallopian tube with six of 25 lymph node biopsies showing metastasis.
  • Six cycles of paclitaxel (175 mg/m2) plus cisplatin (75 mg/m2) combinatin chemotherapy were administered with 3-week intervals between cycles.
  • At the time of writing 12 months after the second-look laparotomy, she was still disease-free.
  • [MeSH-major] Cystadenocarcinoma, Serous / diagnosis. Fallopian Tube Neoplasms / diagnosis. Pelvic Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Aorta, Thoracic. Appendectomy. Cisplatin / administration & dosage. Diagnosis, Differential. Fallopian Tubes / surgery. Female. Humans. Hysterectomy. Lymph Nodes / surgery. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Omentum / surgery. Ovariectomy. Paclitaxel / administration & dosage. Second-Look Surgery

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658603.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 40
  •  go-up   go-down


24. Bodurka DC, Levenback C, Wolf JK, Gano J, Wharton JT, Kavanagh JJ, Gershenson DM: Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol; 2003 Jan 15;21(2):291-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
  • PURPOSE: To evaluate the efficacy and toxicity of irinotecan in patients with metastatic platinum-resistant or platinum-refractory epithelial ovarian cancer or primary peritoneal cancer.
  • Median progression-free survival was 2.8 months (range, 1.1 to 16 months), median duration of response was 1.4 months (range, 0.7 to 10.1 months); median survival from primary diagnosis was 24.3 months (range, 6.5 to 85.7 months); and median survival from initiation of irinotecan was 10.1 months (range, 2.3 to 34 months).
  • No treatment-related deaths occurred.
  • CONCLUSION: Irinotecan has moderate efficacy and substantial toxicity in patients with metastatic platinum-resistant or platinum-refractory epithelial ovarian or primary peritoneal cancer.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Neoplasms, Glandular and Epithelial / drug therapy. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Adult. Aged. CA-125 Antigen / metabolism. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Immunoenzyme Techniques. Infusions, Intravenous. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12525521.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / CA-125 Antigen; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Gordon AN, Asmar L, Messing MJ, Street DG, Pippitt CH Jr, Bailey CL, Savage J, Young JA: Phase II study of sequential doublets: topotecan and carboplatin, followed by paclitaxel and carboplatin, in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol; 2004 Aug;94(2):533-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Incorporating topotecan into standard platinum/taxane chemotherapy for advanced ovarian cancer has been complicated by myelosuppression.
  • Median time to progression was 14 months and actuarial survival was 23 months.
  • Neutropenia was the primary toxicity and cause of dose adjustments and delays, including two deaths.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. CA-125 Antigen / blood. Carboplatin / administration & dosage. Carboplatin / adverse effects. Cystadenocarcinoma, Papillary / blood. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / blood. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Disease-Free Survival. Drug Administration Schedule. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Peritoneal Neoplasms / blood. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Topotecan / administration & dosage. Topotecan / adverse effects

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297200.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 7M7YKX2N15 / Topotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


26. Ivanov S, Ivanov S: [Results of cytoreductive surgery for advanced and recurrent ovarian neoplasms and papillary serous carcinomas of the peritoneum]. Akush Ginekol (Sofiia); 2004;43(5):36-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Results of cytoreductive surgery for advanced and recurrent ovarian neoplasms and papillary serous carcinomas of the peritoneum].
  • The aim of our study was to review and show the long-term results of the cytoreductive surgery in the treatment of advanced primary and recurrent epithelial ovarian cancers and papillary serous carcinomas of the peritoneum.
  • We wanted to find clinical factors and in this way to select patients who can benefit from this kind of treatment.
  • Neoadjuvant and early postoperative chemotherapy were applied in most of the patients.
  • We consider the cytoreductive surgery to be effective only when combined with neoadjuvant or with early postoperative chemotherapy.
  • The surgical approach without chemotherapy leads to bad results.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / surgery. Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Female. Gynecologic Surgical Procedures. Humans. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15518283.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] bul
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


27. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD: Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer; 2009 Jul;19(5):860-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy.
  • To evaluate the potential of epithelial cell adhesion molecule (Ep-CAM/TROP-1)-specific immunotherapy against epithelial ovarian carcinomas (EOCs), we have analyzed the expression of Ep-CAM at RNA and protein level in patients harboring primary, metastatic, and chemotherapy-resistant/recurrent EOC.
  • Epithelial cell adhesion molecule expression was evaluated by real-time polymerase chain reaction and immunohistochemistry in 168 fresh-frozen biopsies and paraffin-embedded tissues.
  • In addition, Ep-CAM surface expression was evaluated by flow cytometry in several freshly established ovarian carcinoma cell lines derived from patients harboring tumors resistant to chemotherapy in vivo as well as in vitro.
  • Epithelial cell adhesion molecule transcript was found significantly overexpressed in primary, metastatic, and recurrent EOC when compared with normal human ovarian surface epithelium cell lines and fresh-frozen normal ovarian tissue (P < 0.001).
  • Similarly, by immunohistochemistry, Ep-CAM protein expression was found significantly higher in primary, metastatic, and recurrent EOC when compared with normal ovarian tissues.
  • Of interest, metastatic/recurrent tumors were found to express significantly higher levels of Ep-CAM protein when compared with primary ovarian carcinomas (P < 0.001).
  • Finally, a high surface expression of Ep-CAM was found in 100% (5/5) of the chemotherapy-resistant ovarian carcinoma cell lines studied by flow cytometry.
  • These results demonstrate high Ep-CAM overexpression in ovarian carcinoma, especially in metastatic and recurrent/chemotherapy-resistant ovarian disease.
  • The lack of Ep-CAM expression on the chelomic epithelium in the peritoneal cavity, combined with the recent development of fully human monoclonal antibodies against this surface molecule, suggest Ep-CAM as a promising target for antibody-mediated therapies in ovarian carcinoma patients harboring tumors refractory to standard treatment modalities.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cell Adhesion Molecules / metabolism. Drug Resistance, Neoplasm. Neoplasm Recurrence, Local / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Blotting, Western. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / secondary. Chemotherapy, Adjuvant. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / metabolism. Endometrial Neoplasms / secondary. Female. Flow Cytometry. Humans. Immunoenzyme Techniques. Middle Aged. Organoplatinum Compounds / administration & dosage. Ovary / metabolism. Ovary / pathology. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Treatment Outcome. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574774.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Organoplatinum Compounds; 0 / RNA, Messenger
  •  go-up   go-down


28. Todoroki T, Murata S, Nakagawa Y, Ohkohchi N, Morishita Y: A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report. Int Semin Surg Oncol; 2006;3:22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-term survivor of repeated inguinal nodes recurrence of papillary serous adenocarcinoma of CUP: case report.
  • BACKGROUND: Tumor spread beyond the peritoneal cavity in cases of papillary serous adenocarcinoma of the unknown primary (CUP) is a rare late event and carries a poor prognosis.
  • Pathological examination revealed the tumors to be metastases of a papillary serous adenocarcinoma with a psammoma body of CUP.
  • On the 28th postoperative day, newly developed asymptomatic small left inguinal node metastases in the setting of a normal CA125 level were removed.
  • Four and a half years after the primary resection, the CA125 level increased again and newly developed asymptomatic metastases were found in the right deep inguinal nodes and extirpated at that time.
  • CONCLUSION: Aggressive resection surgery followed by effective adjuvant chemotherapy is necessary for surviving long time without relapse of poorly prognostic patients with metastases outside of the abdominal cavity from peritoneal papillary serous adenocarcinomas.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3403-10 [10589751.001]
  • [Cites] Oncology (Williston Park). 2001 Mar;15(3 Suppl 5):16-20 [11301835.001]
  • [Cites] Jpn J Cancer Res. 2001 Jun;92(6):704-9 [11429061.001]
  • [Cites] Bull Cancer. 2002 Oct;89(10):869-75 [12441278.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S59-66 [12915904.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):1990-2005 [12957453.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):1003-10 [14997197.001]
  • [Cites] Anticancer Res. 2005 Jan-Feb;25(1B):443-9 [15816609.001]
  • [Cites] DICP. 1990 Mar;24(3):289-95 [2138376.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1091-4 [2400962.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):15-21 [9210704.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Eur J Cancer. 1998 Jul;34(8):1274-81 [9849491.001]
  • (PMID = 16930493.001).
  • [ISSN] 1477-7800
  • [Journal-full-title] International seminars in surgical oncology : ISSO
  • [ISO-abbreviation] Int Semin Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1574334
  •  go-up   go-down


29. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer; 2003 Sep;39(14):1990-2005
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic management of cancer of an unknown primary.
  • Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man.
  • Patients with CUP present with metastatic disease for which the site of origin cannot be identified at the time of diagnosis.
  • The following clinicopathological entities have been recognised: (i) metastatic CUP primarily to the liver or to multiple sites, (ii) metastatic CUP to lymph nodes including the sub-sets involving primarily the mediastinal-retroperitoneal, the axillary, the cervical or the inguinal nodes, (iii) metastatic CUP of peritoneal cavity including the peritoneal papillary serous carcinomatosis in females and the peritoneal non-papillary carcinomatosis in males or females, (iv) metastatic CUP to the lungs with parenchymal metastases or isolated malignant pleural effusion, (v) metastatic CUP to the bones, (vi) metastatic CUP to the brain, (vii) metastatic neuroendocrine carcinomas and (viii) metastatic melanoma of an unknown primary.
  • Extensive work-up with specific pathology investigations (immunohistochemistry, electron microscopy, molecular diagnosis) and modern imaging technology (computed tomography (CT), mammography, Positron Emission Tomography (PET) scan) have resulted in some improvements in diagnosis; however, the primary site remains unknown in most patients, even on autopsy.
  • Several favourable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy and/or locoregional treatment.
  • Identification and treatment of these patients is of paramount importance.
  • The considered responsive sub-sets to platinum-based chemotherapy are the poorly differentiated carcinomas involving the mediastinal-retroperitoneal nodes, the peritoneal papillary serous adenocarcinomatosis in females and the poorly differentiated neuroendocrine carcinomas.
  • Other tumours successfully managed by locoregional treatment with surgery and/or irradiation are the metastatic adenocarcinoma of isolated axillary nodes, metastatic squamous cell carcinoma of cervical nodes, or any other single metastatic site.
  • Empirical chemotherapy benefits some of the patients who do not fit into any favourable sub-set, and should be considered in patients with a good performance status.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / therapy

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2004 Jun;40(9):1454-5 [15177507.001]
  • (PMID = 12957453.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 119
  •  go-up   go-down


30. Zhang C, Cui H, Zhao Y, Liang XD, Wang CH, Li XP, Shen DH, Wang SJ, Wei LH: [Clinical management and prognostic analysis of primary peritoneal neoplasms]. Zhonghua Fu Chan Ke Za Zhi; 2005 Jul;40(7):464-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical management and prognostic analysis of primary peritoneal neoplasms].
  • OBJECTIVE: To investigate the clinical management strategies and prognostic factors of primary peritoneal neoplasms.
  • METHODS: We retrospectively reviewed the clinical and pathological records of 24 cases with primary peritoneal neoplasms treated in the People's Hospital, Peking University during May 1995 and April 2004.
  • RESULTS: Among 24 cases, 15 patients were diagnosed as serous papillary adenocarcinoma (9 highly and intermediately differentiated, and 6 lowly differentiated), 6 as mixed epithelial carcinoma and 3 as mixed malignant Mullerian tumor (MMMT).
  • Then they received a platinum-based chemotherapy.
  • Thirteen cases received paclitaxel + cisplatin (TP) and 9 received cisplatin + doxorubicin + cyclophosphamide (PAC) combination chemotherapy.
  • The primary response reached 80% (complete response 55% and partial response 25%).
  • Survival for patients with primary peritoneal serous papillary carcinoma (PPSPC), mixed epithelial carcinoma and MMMT was 44, 19 and 13 months respectively, with a significant difference between PPSPC and MMMT (P < 0.05).
  • CONCLUSIONS: Patients with primary peritoneal neoplasms should be treated with appropriate cytoreductive surgery.
  • A primary surgical protocol is bilateral salpingo-oophorectomy and omentectomy.
  • TP combination therapy may bring longer survival than PAC regimen.
  • Histopathologic types and chemotherapy regimens are the essential factors of the prognosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Peritoneal Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080873.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F: Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer; 2008 Jan 1;122(1):91-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma.
  • Epithelial ovarian carcinoma (EOC) spreads by implantation of tumor cells onto the human peritoneal mesothelial cells (HPMCs) lining the peritoneal cavity.
  • The aim of this study was to determine whether the stromal cell-derived factor-1alpha (SDF-1alpha)/CXCR4 axis is involved in the interaction of EOC cells with HPMCs in peritoneal metastasis.
  • Clinically, we first evaluated CXCR4 expression in sections from 36 primary EOCs using immunohistochemistry.
  • We next examined whether SDF-1alpha played roles in EOC progression, including in proliferation, cell motility, attachment to HPMCs, and the in vivo development of peritoneal metastasis through CXCR4.
  • Furthermore, intraperitoneal treatment with AMD3100 resulted in reduced dissemination in nude mice inoculated with ES-2 cells.
  • The present results suggest that there may be a link between the SDF-1alpha/CXCR4 axis and enhanced intraperitoneal dissemination of EOC and that CXCR4 may be a novel target for the treatment of EOC.
  • [MeSH-major] Chemokine CXCL12 / metabolism. Ovarian Neoplasms / metabolism. Peritoneal Neoplasms / metabolism. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Adenocarcinoma, Clear Cell / drug therapy. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / secondary. Adenocarcinoma, Mucinous / drug therapy. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / secondary. Adult. Aged. Animals. Anti-HIV Agents / pharmacology. Blotting, Western. Carcinoma, Endometrioid / drug therapy. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / secondary. Cell Adhesion / physiology. Cell Movement / physiology. Coculture Techniques. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / secondary. Enzyme-Linked Immunosorbent Assay. Female. Flow Cytometry. Heterocyclic Compounds / pharmacology. Humans. Immunoenzyme Techniques. Mice. Middle Aged. Mitogen-Activated Protein Kinases / metabolism. Neoplasms, Glandular and Epithelial / drug therapy. Neoplasms, Glandular and Epithelial / metabolism. Neoplasms, Glandular and Epithelial / pathology. Peritoneum / metabolism. Peritoneum / pathology. Phosphatidylinositol 3-Kinases / metabolism. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17893878.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Heterocyclic Compounds; 0 / Receptors, CXCR4; 155148-31-5 / JM 3100; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  •  go-up   go-down


32. Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J: An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer. Gynecol Oncol; 2009 Apr;113(1):63-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
  • OBJECTIVES: To assess the feasibility, associated toxicities, and reasons for early cessation of an outpatient intraperitoneal (IP) chemotherapy regimen for treatment of advanced ovarian cancer following optimal cytoreductive surgery.
  • METHODS: Between January 2006 and December 2007, 42 patients with stages IIC-IV epithelial ovarian, tubal, or primary peritoneal cancer who had residual disease <1 cm after cytoreductive surgery were treated with an outpatient IP chemotherapy protocol.
  • Patients received intravenous (IV) docetaxel 75 mg/m(2) and IP cisplatin 75-100 mg/m(2) on day 1, followed by IP paclitaxel 60 mg/m(2) on day 8, with the intent to treat patients every 21 days for 6 cycles of chemotherapy.
  • Charts were abstracted for demographic, chemotherapy, and toxicity-related data.
  • RESULTS: The median age of the 42 patients was 59 years (range 33-70) and the majority of patients had epithelial ovarian cancer (80%), FIGO stage IIIC (83%), and papillary serous histology (74%).
  • Of an intended 252 IP chemotherapy cycles, 172 (68%) were administered.
  • There was one treatment-related death.
  • Reasons for discontinuation were largely chemotherapy (43%) or port (37%) related.
  • CONCLUSIONS: With supportive measures, such as scheduled hydration and granulocyte colony-stimulating factors, outpatient administration of IP chemotherapy was feasible.
  • This regimen resulted in few hospitalizations or treatment delays and demonstrated less toxicity than previously reported IP chemotherapy regimens.
  • Port-related complications were a leading cause of IP chemotherapy discontinuation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Amifostine / administration & dosage. Cisplatin / administration & dosage. Combined Modality Therapy. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Humans. Infusions, Parenteral. Middle Aged. Neoplasm Staging. Outpatients. Paclitaxel / administration & dosage. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Pilot Projects. Retrospective Studies

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. AMIFOSTINE .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201457.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] M487QF2F4V / Amifostine; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


33. Chen MY, Jung SM, Ng KK, Chang TC: Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:231-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report.
  • Papillary serous adenocarcinoma has been recognized as a highly malignant ovarian cancer and is also not uncommonly seen in primary lung cancer.
  • Difficulty may exist in determining the origin of the primary tumor in women with synchronous pulmonary and ovarian tumors.
  • We present a patient who was initially diagnosed and treated as stage IV papillary serous ovarian cancer with diffuse pulmonary metastases.
  • Only transient symptomatic improvement was achieved after standard chemotherapy for ovarian cancer, and then she died of respiratory distress during treatment.
  • Poor tumor response to chemotherapy prompted us to reevaluate the previous bronchoscopic biopsy, and immunohistochemical studies, which were cytokeratin (CK) 7 positive, CK20 negative, and thyroid transcription factor-1 (TTF-1)-positive, provided irrefutable evidences for the diagnosis of primary lung cancer.
  • We suggest that in dealing with coexistence of ovarian and pulmonary tumors, immunohistochemical study by using CK7, CK20, and TTF-1 may be helpful in the differentiation of the primary origin.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lung Neoplasms / pathology. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515596.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Hochster H, Chen TT, Lu JM, Hills D, Sorich J, Escalon J, Ivy P, Liebes L, Muggia F: Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol; 2008 Mar;108(3):500-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ovarian and primary peritoneal cancer patients, pretreated with at least one prior platinum-containing regimen, performance status (PS) 0-1, without prior pelvic radiation were eligible.
  • RESULTS: Twenty-three patients (20 ovarian, 1 tubal, and 2 peritoneal) were entered: median age 56 years (range, 37-77); PS: 0=12 and 1=11; histology: papillary serous 7, serous 4, adenocarcinoma 8, poorly differentiated 2.
  • A phase II evaluation as second-line treatment for both platinum-sensitive and -resistant ovarian cancer recurrences is ongoing.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Topotecan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Aug;17(8):2553-61 [10561322.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):422-7 [16996118.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3312-22 [11454878.001]
  • [Cites] Ann Oncol. 2002 Mar;13(3):399-402 [11996470.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1888-98 [12204671.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):100-3 [14679127.001]
  • [Cites] Cancer. 2004 Jan 1;100(1):211-2 [14692042.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Aug;54(2):178-84 [15114411.001]
  • [Cites] Biomed Pharmacother. 1989;43(4):237-50 [2675999.001]
  • [Cites] J Pharm Biomed Anal. 1990;8(8-12):789-94 [2100624.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):513-4 [1548513.001]
  • [Cites] J Natl Cancer Inst. 1996 Jun 5;88(11):734-41 [8637027.001]
  • [Cites] Biochem Pharmacol. 1996 Dec 24;52(12):1855-65 [8951344.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3056-61 [8955650.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3074-84 [8955652.001]
  • [Cites] Ann Oncol. 1996 Dec;7(10):1065-70 [9037366.001]
  • [Cites] Cancer Res. 1997 May 15;57(10):1841-5 [9157971.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1400-6 [9337681.001]
  • [Cites] Clin Cancer Res. 1998 Mar;4(3):545-57 [9533521.001]
  • [Cites] Clin Cancer Res. 1997 Aug;3(8):1245-52 [9815806.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5912-9 [16115933.001]
  • [Cites] Gynecol Oncol. 2006 Feb;100(2):324-9 [16253316.001]
  • [Cites] Oncologist. 2006 May;11(5):529-31; author reply 531-2 [16720854.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):473-8 [16631245.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(6):1193-202 [10715288.001]
  • (PMID = 18191187.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA076642-05; United States / NCI NIH HHS / CA / P30 CA016087; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U01 CA076642-04; United States / NCI NIH HHS / CA / U01 CA076642; United States / NCI NIH HHS / CA / CA076642-03; United States / NCI NIH HHS / CM / N01 CM062204; United States / NCI NIH HHS / CA / CA76642; United States / NCI NIH HHS / CM / N01 CM007003; United States / NCI NIH HHS / CA / CA16087; United States / NCI NIH HHS / CA / U01 CA076642-03; United States / NCI NIH HHS / CA / CA076642-04; United States / NCI NIH HHS / CM / N01-CM-07003-74S; United States / NCI NIH HHS / CA / CA21115(-27); United States / NCI NIH HHS / CA / CA076642-05
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 7M7YKX2N15 / Topotecan
  • [Other-IDs] NLM/ NIHMS42700; NLM/ PMC3572735
  •  go-up   go-down






Advertisement